ORBIMED ADVISORS LLC has filed 229 insider transactions across 24 companies since December 2022.
Most recent transaction: a sale of 1890 shares of Sionna Therapeutics, Inc. ($SION) on February 02, 2026.
Activity breakdown: 40 open-market purchases and 151 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | Sionna Therapeutics, Inc. | $SION | ORBIMED ADVISORS LLC | Director | S | Common Stock | 1890 | $44.57 | 3,559,765.0000 | 44,628,788 | 0.05% | 0.00% |
| Feb. 3, 2026 | Sionna Therapeutics, Inc. | $SION | ORBIMED ADVISORS LLC | Director | S | Common Stock | 29063 | $44.58 | 3,530,702.0000 | 44,628,788 | 0.82% | 0.07% |
| Dec. 24, 2025 | Sionna Therapeutics, Inc. | $SION | ORBIMED ADVISORS LLC | Director | S | Common Stock | 33356 | $44.55 | 3,561,655.0000 | 44,628,788 | 0.93% | 0.07% |
| Dec. 18, 2025 | Sionna Therapeutics, Inc. | $SION | ORBIMED ADVISORS LLC | Director | S | Common Stock | 100 | $44.49 | 3,595,886.0000 | 44,628,788 | 0.00% | 0.00% |
| Dec. 17, 2025 | Sionna Therapeutics, Inc. | $SION | ORBIMED ADVISORS LLC | Director | S | Common Stock | 900 | $44.50 | 3,595,986.0000 | 44,628,788 | 0.03% | 0.00% |
| Dec. 19, 2025 | Sionna Therapeutics, Inc. | $SION | ORBIMED ADVISORS LLC | Director | S | Common Stock | 875 | $44.49 | 3,595,011.0000 | 44,628,788 | 0.02% | 0.00% |
| Nov. 21, 2025 | Keros Therapeutics, Inc. | $KROS | ORBIMED ADVISORS LLC | Director | D | Common Stock | 74465 | $17.75 | 45,057.0000 | 41,202,371 | 62.30% | 0.18% |
| Nov. 21, 2025 | Keros Therapeutics, Inc. | $KROS | ORBIMED ADVISORS LLC | Director | D | Common Stock | 140057 | $17.75 | 759,155.0000 | 41,202,371 | 15.58% | 0.34% |
| Nov. 24, 2025 | Sionna Therapeutics, Inc. | $SION | ORBIMED ADVISORS LLC | Director | S | Common Stock | 94583 | $44.54 | 3,610,376.0000 | 44,628,788 | 2.55% | 0.21% |
| Nov. 26, 2025 | Sionna Therapeutics, Inc. | $SION | ORBIMED ADVISORS LLC | Director | S | Common Stock | 1600 | $44.49 | 3,596,886.0000 | 44,628,788 | 0.04% | 0.00% |
| Nov. 25, 2025 | Sionna Therapeutics, Inc. | $SION | ORBIMED ADVISORS LLC | Director | S | Common Stock | 11890 | $44.60 | 3,598,486.0000 | 44,628,788 | 0.33% | 0.03% |
| Oct. 23, 2025 | PMV Pharmaceuticals, Inc. | $PMVP | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 1000000 | $1.52 | 4,975,291.0000 | 51,933,604 | 16.74% | 1.93% |
| Oct. 8, 2025 | Adicet Bio, Inc. | $ACET | ORBIMED ADVISORS LLC | TenPercentOwner | P | Common Stock | 3500000 | $1.00 | 7,420,781.0000 | 82,685,750 | 89.27% | 4.23% |
| Oct. 8, 2025 | Adicet Bio, Inc. | $ACET | ORBIMED ADVISORS LLC | TenPercentOwner | P | Common Stock | 1500000 | $1.00 | 11,956,886.0000 | 82,685,750 | 14.34% | 1.81% |
| Sept. 10, 2025 | PMV Pharmaceuticals, Inc. | $PMVP | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 500000 | $1.80 | 5,975,291.0000 | 51,933,604 | 7.72% | 0.96% |
| Aug. 25, 2025 | Shattuck Labs, Inc. | $STTK | ORBIMED ADVISORS LLC | Director | P | Common Warrants (right to buy) | 3073298 | $0.00 | 3,073,298.0000 | 50,758,290 | 9999.99% | 6.05% |
| Aug. 25, 2025 | Shattuck Labs, Inc. | $STTK | ORBIMED ADVISORS LLC | Director | P | Common Warrants (right to buy) | 15366490 | $0.00 | 15,366,490.0000 | 50,758,290 | 9999.99% | 30.27% |
| Aug. 25, 2025 | Shattuck Labs, Inc. | $STTK | ORBIMED ADVISORS LLC | Director | P | Common Stock | 1051021 | $0.87 | 1,051,021.0000 | 50,758,290 | 9999.99% | 2.07% |
| Aug. 25, 2025 | Shattuck Labs, Inc. | $STTK | ORBIMED ADVISORS LLC | Director | P | Pre-Funded Warrants (right to buy) | 10111384 | $0.00 | 10,111,384.0000 | 50,758,290 | 9999.99% | 19.92% |
| Aug. 25, 2025 | Shattuck Labs, Inc. | $STTK | ORBIMED ADVISORS LLC | Director | P | Pre-Funded Warrants (right to buy) | 2022277 | $0.00 | 2,022,277.0000 | 50,758,290 | 9999.99% | 3.98% |
| Aug. 25, 2025 | Shattuck Labs, Inc. | $STTK | ORBIMED ADVISORS LLC | Director | P | Common Stock | 5255106 | $0.87 | 5,255,106.0000 | 50,758,290 | 9999.99% | 10.35% |
| Aug. 8, 2025 | Turnstone Biologics Corp. | $TSBX | ORBIMED ADVISORS LLC | Director | U | Common Stock | 3099265 | $0.00 | 0.0000 | 23,138,896 | 100.00% | 13.39% |
| July 25, 2025 | ImageneBio, Inc. | $IMA | ORBIMED ADVISORS LLC | Director | A | Common Stock | 83611 | $2.49 | 295,469.0000 | 48,258,111 | 39.47% | 0.17% |
| June 27, 2025 | Corvus Pharmaceuticals, Inc. | $CRVS | ORBIMED ADVISORS LLC | Director | X | Common Stock | 1397684 | $3.50 | 8,341,338.0000 | 75,152,514 | 20.13% | 1.86% |
| June 27, 2025 | Corvus Pharmaceuticals, Inc. | $CRVS | ORBIMED ADVISORS LLC | Director | X | Common Warrants (right to buy) | 1397684 | $0.00 | 0.0000 | 75,152,514 | 100.00% | 1.86% |
| June 27, 2025 | Corvus Pharmaceuticals, Inc. | $CRVS | ORBIMED ADVISORS LLC | Director | S | Common Stock | 1176332 | $4.16 | 7,165,006.0000 | 75,152,514 | 14.10% | 1.57% |
| June 24, 2025 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 231600 | $0.35 | 6,418,400.0000 | 62,109,991 | 3.48% | 0.37% |
| June 25, 2025 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 138800 | $0.33 | 6,279,600.0000 | 62,109,991 | 2.16% | 0.22% |
| June 26, 2025 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 213257 | $0.33 | 6,066,343.0000 | 62,109,991 | 3.40% | 0.34% |
| May 14, 2025 | NeuroPace Inc | $NPCE | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 134136 | $15.83 | 3,272,199.0000 | 32,560,130 | 3.94% | 0.41% |
| May 14, 2025 | NeuroPace Inc | $NPCE | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 34000 | $15.94 | 3,238,199.0000 | 32,560,130 | 1.04% | 0.10% |
| April 23, 2025 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 89328 | $0.34 | 6,718,195.0000 | 62,109,991 | 1.31% | 0.14% |
| April 22, 2025 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 78049 | $0.34 | 6,807,523.0000 | 62,109,991 | 1.13% | 0.13% |
| April 24, 2025 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 68195 | $0.32 | 6,650,000.0000 | 62,109,991 | 1.02% | 0.11% |
| April 17, 2025 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 77090 | $0.33 | 6,885,572.0000 | 62,109,991 | 1.11% | 0.12% |
| April 16, 2025 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 61638 | $0.33 | 6,962,662.0000 | 62,109,991 | 0.88% | 0.10% |
| April 15, 2025 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 10326 | $0.38 | 7,024,300.0000 | 62,109,991 | 0.15% | 0.02% |
| April 10, 2025 | Xtant Medical Holdings, Inc. | $XTNT | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 17109618 | $0.42 | 0.0000 | 133,665,075 | 100.00% | 12.80% |
| April 10, 2025 | Xtant Medical Holdings, Inc. | $XTNT | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 56004974 | $0.42 | 0.0000 | 133,665,075 | 100.00% | 41.90% |
| April 9, 2025 | Compass Therapeutics, Inc. | $CMPX | ORBIMED ADVISORS LLC | Director | S | Common Stock | 3571428 | $1.59 | 15,219,994.0000 | 138,282,498 | 19.01% | 2.58% |
| April 3, 2025 | Edgewise Therapeutics, Inc. | $EWTX | ORBIMED ADVISORS LLC | Director | P | Common Stock | 124193 | $20.13 | 443,792.0000 | 95,130,053 | 38.86% | 0.13% |
| April 3, 2025 | Edgewise Therapeutics, Inc. | $EWTX | ORBIMED ADVISORS LLC | Director | P | Common Stock | 372578 | $20.13 | 14,809,075.0000 | 95,130,053 | 2.58% | 0.39% |
| March 24, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 1956 | $54.11 | 482,308.0000 | 34,569,042 | 0.40% | 0.01% |
| March 24, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 3026 | $54.11 | 746,171.0000 | 34,569,042 | 0.40% | 0.01% |
| March 24, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 756 | $54.11 | 186,541.0000 | 34,569,042 | 0.40% | 0.00% |
| March 21, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 5279 | $54.00 | 749,197.0000 | 34,569,042 | 0.70% | 0.02% |
| March 21, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 3412 | $54.00 | 484,264.0000 | 34,569,042 | 0.70% | 0.01% |
| March 20, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 1457 | $54.01 | 754,476.0000 | 34,569,042 | 0.19% | 0.00% |
| March 20, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 364 | $54.01 | 188,617.0000 | 34,569,042 | 0.19% | 0.00% |
| March 19, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 5228 | $54.02 | 188,981.0000 | 34,569,042 | 2.69% | 0.02% |
| March 19, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 20911 | $54.02 | 755,933.0000 | 34,569,042 | 2.69% | 0.06% |
| March 19, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 13517 | $54.02 | 488,617.0000 | 34,569,042 | 2.69% | 0.04% |
| March 21, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 1320 | $54.00 | 187,297.0000 | 34,569,042 | 0.70% | 0.00% |
| March 20, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 941 | $54.01 | 487,676.0000 | 34,569,042 | 0.19% | 0.00% |
| March 12, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 233 | $55.05 | 204,942.0000 | 34,569,042 | 0.11% | 0.00% |
| March 10, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 68766 | $54.29 | 539,845.0000 | 34,569,042 | 11.30% | 0.20% |
| March 10, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 106384 | $54.29 | 835,185.0000 | 34,569,042 | 11.30% | 0.31% |
| March 10, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 26596 | $54.29 | 208,795.0000 | 34,569,042 | 11.30% | 0.08% |
| March 10, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 136 | $55.01 | 539,709.0000 | 34,569,042 | 0.03% | 0.00% |
| March 10, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 211 | $55.01 | 834,974.0000 | 34,569,042 | 0.03% | 0.00% |
| March 10, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 53 | $55.01 | 208,742.0000 | 34,569,042 | 0.03% | 0.00% |
| March 11, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 9222 | $54.01 | 530,487.0000 | 34,569,042 | 1.71% | 0.03% |
| March 11, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 14267 | $54.01 | 820,707.0000 | 34,569,042 | 1.71% | 0.04% |
| March 11, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 3567 | $54.01 | 205,175.0000 | 34,569,042 | 1.71% | 0.01% |
| March 12, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 603 | $55.05 | 529,884.0000 | 34,569,042 | 0.11% | 0.00% |
| March 12, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 933 | $55.05 | 819,774.0000 | 34,569,042 | 0.11% | 0.00% |
| March 12, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 27750 | $54.44 | 502,134.0000 | 34,569,042 | 5.24% | 0.08% |
| March 12, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 42930 | $54.44 | 776,844.0000 | 34,569,042 | 5.24% | 0.12% |
| March 12, 2025 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 10733 | $54.44 | 194,209.0000 | 34,569,042 | 5.24% | 0.03% |
| Feb. 14, 2025 | MBX Biosciences, Inc. | $MBX | ORBIMED ADVISORS LLC | Director | P | Common Stock | 29540 | $9.85 | 3,205,930.0000 | 0 | 0.93% | 0.00% |
| Feb. 14, 2025 | MBX Biosciences, Inc. | $MBX | ORBIMED ADVISORS LLC | Director | P | Common Stock | 17962 | $9.90 | 3,176,390.0000 | 0 | 0.57% | 0.00% |
| Feb. 18, 2025 | MBX Biosciences, Inc. | $MBX | ORBIMED ADVISORS LLC | Director | P | Common Stock | 49070 | $10.84 | 3,255,000.0000 | 0 | 1.53% | 0.00% |
| Feb. 18, 2025 | MBX Biosciences, Inc. | $MBX | ORBIMED ADVISORS LLC | Director | P | Common Stock | 94100 | $10.84 | 747,887.0000 | 0 | 14.39% | 0.00% |
| Feb. 10, 2025 | Sionna Therapeutics, Inc. | $SION | ORBIMED ADVISORS LLC | Director | C | Common Stock | 3154959 | $0.00 | 3,154,959.0000 | 0 | 9999.99% | 0.00% |
| Feb. 10, 2025 | Sionna Therapeutics, Inc. | $SION | ORBIMED ADVISORS LLC | Director | C | Series C convertible preferred stock | 2048760 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 10, 2025 | Sionna Therapeutics, Inc. | $SION | ORBIMED ADVISORS LLC | Director | C | Series B convertible preferred stock | 2560951 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 10, 2025 | Sionna Therapeutics, Inc. | $SION | ORBIMED ADVISORS LLC | Director | P | Common Stock | 550000 | $18.00 | 3,704,959.0000 | 0 | 17.43% | 0.00% |
| Dec. 29, 2024 | Traws Pharma, Inc. | $TRAW | ORBIMED ADVISORS LLC | TenPercentOwner | P | Pre-Funded Warrant (right to buy) | 96348 | $0.00 | 96,348.0000 | 961,530 | 9999.99% | 10.02% |
| Dec. 29, 2024 | Traws Pharma, Inc. | $TRAW | ORBIMED ADVISORS LLC | TenPercentOwner | P | Series A Warrant (right to buy) | 96348 | $0.00 | 96,348.0000 | 961,530 | 9999.99% | 10.02% |
| Jan. 10, 2025 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 126209 | $0.66 | 7,131,636.0000 | 3,078,665 | 1.74% | 4.10% |
| Jan. 13, 2025 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 17986 | $0.64 | 7,113,650.0000 | 3,078,665 | 0.25% | 0.58% |
| Jan. 14, 2025 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 79024 | $0.60 | 7,034,626.0000 | 3,078,665 | 1.11% | 2.57% |
| Jan. 8, 2025 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 75007 | $0.68 | 7,257,845.0000 | 3,078,665 | 1.02% | 2.44% |
| Jan. 6, 2025 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 19481 | $0.77 | 7,385,388.0000 | 3,078,665 | 0.26% | 0.63% |
| Jan. 7, 2025 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 52536 | $0.71 | 7,332,852.0000 | 3,078,665 | 0.71% | 1.71% |
| Dec. 20, 2024 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 230321 | $0.60 | 7,404,869.0000 | 3,146,582 | 3.02% | 7.32% |
| Dec. 10, 2024 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 8015 | $0.80 | 7,635,270.0000 | 3,146,582 | 0.10% | 0.25% |
| Dec. 11, 2024 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 80 | $0.80 | 7,635,190.0000 | 3,146,582 | 0.00% | 0.00% |
| Dec. 9, 2024 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 54181 | $0.84 | 7,643,285.0000 | 3,146,582 | 0.70% | 1.72% |
| Dec. 4, 2024 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 76200 | $0.79 | 7,718,369.0000 | 3,146,582 | 0.98% | 2.42% |
| Dec. 6, 2024 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 20903 | $0.82 | 7,697,466.0000 | 3,146,582 | 0.27% | 0.66% |
| Oct. 15, 2024 | Upstream Bio, Inc. | $UPB | ORBIMED ADVISORS LLC | Director | C | Series B redeemable convertible preferred stock | 789833 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Oct. 15, 2024 | Upstream Bio, Inc. | $UPB | ORBIMED ADVISORS LLC | Director | P | Common Stock | 660000 | $17.00 | 4,554,873.0000 | 0 | 16.95% | 0.00% |
| Oct. 15, 2024 | Upstream Bio, Inc. | $UPB | ORBIMED ADVISORS LLC | Director | C | Series A redeemable convertible preferred stock | 524500 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Oct. 15, 2024 | Upstream Bio, Inc. | $UPB | ORBIMED ADVISORS LLC | Director | C | Series A redeemable convertible preferred stock | 2098000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Oct. 15, 2024 | Upstream Bio, Inc. | $UPB | ORBIMED ADVISORS LLC | Director | C | Series B redeemable convertible preferred stock | 197456 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Oct. 15, 2024 | Upstream Bio, Inc. | $UPB | ORBIMED ADVISORS LLC | Director | C | Common Stock | 721956 | $0.00 | 973,716.0000 | 0 | 286.76% | 0.00% |
| Oct. 15, 2024 | Upstream Bio, Inc. | $UPB | ORBIMED ADVISORS LLC | Director | P | Common Stock | 165000 | $17.00 | 1,138,716.0000 | 0 | 16.95% | 0.00% |
| Oct. 15, 2024 | Upstream Bio, Inc. | $UPB | ORBIMED ADVISORS LLC | Director | C | Common Stock | 2887833 | $0.00 | 3,894,873.0000 | 0 | 286.76% | 0.00% |
| Sept. 19, 2024 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 39300 | $0.71 | 7,794,569.0000 | 3,142,537 | 0.50% | 1.25% |
| Sept. 18, 2024 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 25631 | $0.73 | 7,833,869.0000 | 3,142,537 | 0.33% | 0.82% |
| Sept. 17, 2024 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 111400 | $0.73 | 7,859,500.0000 | 3,142,537 | 1.40% | 3.54% |
| Sept. 16, 2024 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 63100 | $0.74 | 7,970,900.0000 | 3,142,537 | 0.79% | 2.01% |
| Sept. 16, 2024 | MBX Biosciences, Inc. | $MBX | ORBIMED ADVISORS LLC | Not found | P | Common Stock | 250000 | $16.00 | 3,812,215.0000 | 0 | 7.02% | 0.00% |
| Sept. 16, 2024 | MBX Biosciences, Inc. | $MBX | ORBIMED ADVISORS LLC | Not found | C | Series A Convertible Preferred Stock | 12372634 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Sept. 16, 2024 | MBX Biosciences, Inc. | $MBX | ORBIMED ADVISORS LLC | Not found | C | Series B Convertible Preferred Stock | 19587284 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Sept. 16, 2024 | MBX Biosciences, Inc. | $MBX | ORBIMED ADVISORS LLC | Not found | C | Series C Convertible Preferred Stock | 4854368 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Sept. 16, 2024 | MBX Biosciences, Inc. | $MBX | ORBIMED ADVISORS LLC | Not found | C | Common Stock | 2658428 | $0.00 | 3,312,215.0000 | 0 | 406.62% | 0.00% |
| Sept. 16, 2024 | MBX Biosciences, Inc. | $MBX | ORBIMED ADVISORS LLC | Not found | C | Common Stock | 403787 | $0.00 | 3,562,215.0000 | 0 | 12.78% | 0.00% |
| Sept. 16, 2024 | MBX Biosciences, Inc. | $MBX | ORBIMED ADVISORS LLC | Not found | P | Common Stock | 500000 | $16.00 | 3,812,215.0000 | 0 | 15.10% | 0.00% |
| Aug. 26, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | ORBIMED ADVISORS LLC | Director | S | Common Stock | 83695 | $13.00 | 8,288,510.0000 | 95,215,322 | 1.00% | 0.09% |
| Aug. 23, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | ORBIMED ADVISORS LLC | Director | S | Common Stock | 69500 | $13.03 | 8,372,205.0000 | 95,215,322 | 0.82% | 0.07% |
| Aug. 22, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | ORBIMED ADVISORS LLC | Director | S | Common Stock | 391482 | $12.94 | 8,441,705.0000 | 95,215,322 | 4.43% | 0.41% |
| Aug. 21, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | ORBIMED ADVISORS LLC | Director | S | Common Stock | 13300 | $14.61 | 8,833,187.0000 | 95,215,322 | 0.15% | 0.01% |
| Aug. 21, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | ORBIMED ADVISORS LLC | Director | S | Common Stock | 394400 | $13.52 | 8,846,487.0000 | 95,215,322 | 4.27% | 0.41% |
| Aug. 13, 2024 | Keros Therapeutics, Inc. | $KROS | ORBIMED ADVISORS LLC | Director | S | Common Stock | 29400 | $44.01 | 119,522.0000 | 29,447,119 | 19.74% | 0.10% |
| Aug. 13, 2024 | scPharmaceuticals Inc. | $SCPH | ORBIMED ADVISORS LLC | TenPercentOwner | P | Common Stock | 21658 | $4.00 | 252,858.0000 | 38,984,745 | 9.37% | 0.06% |
| Aug. 13, 2024 | scPharmaceuticals Inc. | $SCPH | ORBIMED ADVISORS LLC | TenPercentOwner | P | Common Stock | 478342 | $4.00 | 5,806,670.0000 | 38,984,745 | 8.98% | 1.23% |
| Aug. 13, 2024 | Keros Therapeutics, Inc. | $KROS | ORBIMED ADVISORS LLC | Director | S | Common Stock | 220600 | $44.01 | 899,212.0000 | 29,447,119 | 19.70% | 0.75% |
| July 16, 2024 | Terns Pharmaceuticals, Inc. | $TERN | ORBIMED ADVISORS LLC | Director | S | Common Stock | 556 | $10.00 | 1,967,924.0000 | 71,259,239 | 0.03% | 0.00% |
| July 15, 2024 | Terns Pharmaceuticals, Inc. | $TERN | ORBIMED ADVISORS LLC | Director | S | Common Stock | 6142 | $10.00 | 756,258.0000 | 71,259,239 | 0.81% | 0.01% |
| July 15, 2024 | Terns Pharmaceuticals, Inc. | $TERN | ORBIMED ADVISORS LLC | Director | S | Common Stock | 5401 | $10.00 | 1,968,480.0000 | 71,259,239 | 0.27% | 0.01% |
| July 15, 2024 | Terns Pharmaceuticals, Inc. | $TERN | ORBIMED ADVISORS LLC | Director | S | Common Stock | 39433 | $10.00 | 4,843,421.0000 | 71,259,239 | 0.81% | 0.06% |
| July 16, 2024 | Terns Pharmaceuticals, Inc. | $TERN | ORBIMED ADVISORS LLC | Director | S | Common Stock | 4009 | $10.00 | 4,839,412.0000 | 71,259,239 | 0.08% | 0.01% |
| July 16, 2024 | Terns Pharmaceuticals, Inc. | $TERN | ORBIMED ADVISORS LLC | Director | S | Common Stock | 623 | $10.00 | 755,635.0000 | 71,259,239 | 0.08% | 0.00% |
| June 28, 2024 | TELA Bio, Inc. | $TELA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 378000 | $4.74 | 2,457,542.0000 | 24,579,386 | 13.33% | 1.54% |
| July 2, 2024 | TELA Bio, Inc. | $TELA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 36600 | $4.54 | 2,407,242.0000 | 24,663,234 | 1.50% | 0.15% |
| July 1, 2024 | TELA Bio, Inc. | $TELA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 13700 | $4.68 | 2,443,842.0000 | 24,663,234 | 0.56% | 0.06% |
| June 17, 2024 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | P | Common Stock | 43944 | $36.00 | 941,569.0000 | 0 | 4.90% | 0.00% |
| June 17, 2024 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | P | Common Stock | 28404 | $36.00 | 608,611.0000 | 0 | 4.90% | 0.00% |
| June 17, 2024 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | P | Common Stock | 10986 | $36.00 | 235,391.0000 | 0 | 4.90% | 0.00% |
| May 16, 2024 | Enliven Therapeutics, Inc. | $ELVN | ORBIMED ADVISORS LLC | Director | S | Common Stock | 1000000 | $22.14 | 7,663,349.0000 | 35,546,215 | 11.54% | 2.81% |
| May 16, 2024 | Enliven Therapeutics, Inc. | $ELVN | ORBIMED ADVISORS LLC | Director | S | Common Stock | 33300 | $22.14 | 254,814.0000 | 35,546,215 | 11.56% | 0.09% |
| May 6, 2024 | Corvus Pharmaceuticals, Inc. | $CRVS | ORBIMED ADVISORS LLC | Director | P | Pre-Funded Warrants (right to buy) | 1444085 | $1.73 | 1,444,085.0000 | 49,038,582 | 9999.99% | 2.94% |
| May 6, 2024 | Corvus Pharmaceuticals, Inc. | $CRVS | ORBIMED ADVISORS LLC | Director | P | Common Warrants (right to buy) | 1397684 | $0.00 | 1,397,684.0000 | 49,038,582 | 9999.99% | 2.85% |
| May 2, 2024 | NeuroPace Inc | $NPCE | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 8842 | $14.01 | 3,411,009.0000 | 0 | 0.26% | 0.00% |
| May 3, 2024 | NeuroPace Inc | $NPCE | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 4674 | $14.03 | 3,406,335.0000 | 0 | 0.14% | 0.00% |
| May 1, 2024 | NeuroPace Inc | $NPCE | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 15690 | $14.02 | 3,419,851.0000 | 0 | 0.46% | 0.00% |
| April 24, 2024 | NeuroPace Inc | $NPCE | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 1781 | $14.06 | 3,435,541.0000 | 0 | 0.05% | 0.00% |
| April 19, 2024 | NeuroPace Inc | $NPCE | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 18253 | $14.02 | 3,483,722.0000 | 0 | 0.52% | 0.00% |
| April 23, 2024 | NeuroPace Inc | $NPCE | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 21791 | $14.29 | 3,437,322.0000 | 0 | 0.63% | 0.00% |
| April 22, 2024 | NeuroPace Inc | $NPCE | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 24609 | $14.05 | 3,459,113.0000 | 0 | 0.71% | 0.00% |
| April 17, 2024 | NeuroPace Inc | $NPCE | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 300 | $14.15 | 3,504,598.0000 | 0 | 0.01% | 0.00% |
| April 16, 2024 | NeuroPace Inc | $NPCE | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 14069 | $14.01 | 3,504,898.0000 | 0 | 0.40% | 0.00% |
| April 18, 2024 | NeuroPace Inc | $NPCE | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 2623 | $14.06 | 3,501,975.0000 | 0 | 0.07% | 0.00% |
| April 12, 2024 | NeuroPace Inc | $NPCE | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 23101 | $14.42 | 3,518,967.0000 | 0 | 0.65% | 0.00% |
| April 11, 2024 | NeuroPace Inc | $NPCE | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 461899 | $14.49 | 3,542,068.0000 | 0 | 11.54% | 0.00% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | ORBIMED ADVISORS LLC | Director | C | Common Stock | 821827 | $0.00 | 821,827.0000 | 2,140,951 | 9999.99% | 38.39% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | ORBIMED ADVISORS LLC | Director | P | Common Stock | 222222 | $18.00 | 1,513,664.0000 | 2,140,951 | 17.21% | 10.38% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | ORBIMED ADVISORS LLC | Director | P | Common Stock | 222222 | $18.00 | 1,513,664.0000 | 2,140,951 | 17.21% | 10.38% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | ORBIMED ADVISORS LLC | Director | C | Common Stock | 821827 | $0.00 | 821,827.0000 | 2,140,951 | 9999.99% | 38.39% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | ORBIMED ADVISORS LLC | Director | C | Series A Preferred Stock | 821827 | $0.00 | 0.0000 | 2,140,951 | 100.00% | 38.39% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | ORBIMED ADVISORS LLC | Director | C | Series A Preferred Stock | 821827 | $0.00 | 0.0000 | 2,140,951 | 100.00% | 38.39% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | ORBIMED ADVISORS LLC | Director | C | Common Stock | 469615 | $0.00 | 1,291,442.0000 | 2,140,951 | 57.14% | 21.94% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | ORBIMED ADVISORS LLC | Director | C | Common Stock | 469615 | $0.00 | 1,291,442.0000 | 2,140,951 | 57.14% | 21.94% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | ORBIMED ADVISORS LLC | Director | C | Series B Preferred Stock | 469615 | $0.00 | 0.0000 | 2,140,951 | 100.00% | 21.94% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | ORBIMED ADVISORS LLC | Director | C | Series B Preferred Stock | 469615 | $0.00 | 0.0000 | 2,140,951 | 100.00% | 21.94% |
| Jan. 25, 2024 | Adicet Bio, Inc. | $ACET | ORBIMED ADVISORS LLC | Not found | P | Common Stock | 1841100 | $2.40 | 9,200,901.0000 | 0 | 25.02% | 0.00% |
| Jan. 25, 2024 | Adicet Bio, Inc. | $ACET | ORBIMED ADVISORS LLC | Not found | P | Common Stock | 242200 | $2.40 | 2,664,796.0000 | 0 | 10.00% | 0.00% |
| Jan. 25, 2024 | Adicet Bio, Inc. | $ACET | ORBIMED ADVISORS LLC | Not found | P | Common Stock | 1041700 | $2.40 | 2,930,527.0000 | 0 | 55.15% | 0.00% |
| Jan. 23, 2024 | Edgewise Therapeutics, Inc. | $EWTX | ORBIMED ADVISORS LLC | Director | P | Common Stock | 454545 | $11.00 | 14,756,096.0000 | 63,723,600 | 3.18% | 0.71% |
| Dec. 18, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | M | Common Stock | 1724 | $38.00 | 1,703,961.0000 | 0 | 0.10% | 0.00% |
| Dec. 18, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 1724 | $59.24 | 1,702,237.0000 | 0 | 0.10% | 0.00% |
| Dec. 18, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | M | Stock Options (Right to Buy) | 1724 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Dec. 14, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 57100 | $56.75 | 224,405.0000 | 0 | 20.28% | 0.00% |
| Dec. 14, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 228500 | $56.75 | 897,625.0000 | 0 | 20.29% | 0.00% |
| Dec. 14, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 147600 | $56.75 | 580,207.0000 | 0 | 20.28% | 0.00% |
| Dec. 12, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 14400 | $60.16 | 1,182,425.0000 | 0 | 1.20% | 0.00% |
| Dec. 12, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 9300 | $60.16 | 764,307.0000 | 0 | 1.20% | 0.00% |
| Dec. 12, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 3600 | $60.16 | 295,605.0000 | 0 | 1.20% | 0.00% |
| Dec. 13, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 56200 | $58.56 | 1,126,225.0000 | 0 | 4.75% | 0.00% |
| Dec. 13, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 14100 | $58.56 | 281,505.0000 | 0 | 4.77% | 0.00% |
| Dec. 13, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 36400 | $58.56 | 727,907.0000 | 0 | 4.76% | 0.00% |
| Dec. 14, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 100 | $57.73 | 727,807.0000 | 0 | 0.01% | 0.00% |
| Dec. 14, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | S | Common Stock | 100 | $57.73 | 1,126,125.0000 | 0 | 0.01% | 0.00% |
| Nov. 22, 2023 | PMV Pharmaceuticals, Inc. | $PMVP | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 87786 | $2.23 | 6,475,291.0000 | 0 | 1.34% | 0.00% |
| Aug. 29, 2023 | ARS Pharmaceuticals, Inc. | $SPRY | ORBIMED ADVISORS LLC | Director | P | Common Stock | 500000 | $6.20 | 9,240,887.0000 | 0 | 5.72% | 0.00% |
| Aug. 15, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 535534 | $0.75 | 1,510,375.0000 | 0 | 26.18% | 0.00% |
| Aug. 15, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 248819 | $0.75 | 631,048.0000 | 0 | 28.28% | 0.00% |
| Aug. 15, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 38327 | $0.75 | 97,204.0000 | 0 | 28.28% | 0.00% |
| July 31, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 26622 | $3.00 | 135,531.0000 | 0 | 16.42% | 0.00% |
| July 31, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 153078 | $3.00 | 2,105,909.0000 | 0 | 6.78% | 0.00% |
| July 31, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 29700 | $3.00 | 879,867.0000 | 0 | 3.27% | 0.00% |
| July 25, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 4700 | $2.92 | 909,567.0000 | 0 | 0.51% | 0.00% |
| July 25, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 26700 | $2.92 | 2,258,987.0000 | 0 | 1.17% | 0.00% |
| July 25, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 7800 | $2.92 | 162,153.0000 | 0 | 4.59% | 0.00% |
| July 13, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 52800 | $2.40 | 914,267.0000 | 0 | 5.46% | 0.00% |
| July 13, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 132100 | $2.40 | 2,285,687.0000 | 0 | 5.46% | 0.00% |
| July 13, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 9800 | $2.40 | 169,953.0000 | 0 | 5.45% | 0.00% |
| June 28, 2023 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | P | Common Stock | 575195 | $0.84 | 8,034,000.0000 | 54,618,799 | 7.71% | 1.05% |
| June 27, 2023 | Passage BIO, Inc. | $PASG | ORBIMED ADVISORS LLC | TenPercentOwner | P | Common Stock | 617382 | $0.84 | 7,458,805.0000 | 54,618,799 | 9.02% | 1.13% |
| May 17, 2023 | Enliven Therapeutics, Inc. | $ELVN | ORBIMED ADVISORS LLC | Director | M | Stock Options (Right to Buy) | 2125 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| May 17, 2023 | Enliven Therapeutics, Inc. | $ELVN | ORBIMED ADVISORS LLC | Director | M | Common Stock | 2125 | $4.28 | 8,951,463.0000 | 0 | 0.02% | 0.00% |
| April 19, 2023 | TELA Bio, Inc. | $TELA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 136000 | $9.30 | 2,891,542.0000 | 19,185,621 | 4.49% | 0.71% |
| April 21, 2023 | TELA Bio, Inc. | $TELA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 27700 | $9.41 | 2,835,542.0000 | 19,185,621 | 0.97% | 0.14% |
| April 20, 2023 | TELA Bio, Inc. | $TELA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 28300 | $9.43 | 2,863,242.0000 | 19,185,621 | 0.98% | 0.15% |
| April 17, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 3551 | $1.97 | 967,067.0000 | 0 | 0.37% | 0.00% |
| April 13, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 703 | $1.82 | 182,504.0000 | 0 | 0.38% | 0.00% |
| April 13, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 3784 | $1.82 | 981,863.0000 | 0 | 0.38% | 0.00% |
| April 13, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 9459 | $1.82 | 2,454,775.0000 | 0 | 0.38% | 0.00% |
| April 14, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 2091 | $1.86 | 180,413.0000 | 0 | 1.15% | 0.00% |
| April 14, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 11245 | $1.86 | 970,618.0000 | 0 | 1.15% | 0.00% |
| April 14, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 28110 | $1.86 | 2,426,665.0000 | 0 | 1.15% | 0.00% |
| April 17, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 660 | $1.97 | 179,753.0000 | 0 | 0.37% | 0.00% |
| April 17, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 8878 | $1.97 | 2,417,787.0000 | 0 | 0.37% | 0.00% |
| April 12, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 641 | $1.81 | 985,647.0000 | 0 | 0.06% | 0.00% |
| April 12, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 1603 | $1.81 | 2,464,234.0000 | 0 | 0.07% | 0.00% |
| April 10, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 2584 | $1.79 | 185,910.0000 | 0 | 1.37% | 0.00% |
| April 10, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 13899 | $1.79 | 1,000,187.0000 | 0 | 1.37% | 0.00% |
| April 10, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 34745 | $1.79 | 2,500,582.0000 | 0 | 1.37% | 0.00% |
| April 11, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 703 | $1.82 | 183,326.0000 | 0 | 0.38% | 0.00% |
| April 11, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 3784 | $1.82 | 986,288.0000 | 0 | 0.38% | 0.00% |
| April 11, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 9459 | $1.82 | 2,465,837.0000 | 0 | 0.38% | 0.00% |
| April 12, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 119 | $1.81 | 183,207.0000 | 0 | 0.06% | 0.00% |
| April 6, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 487 | $2.00 | 186,613.0000 | 0 | 0.26% | 0.00% |
| April 6, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 6558 | $2.00 | 2,510,041.0000 | 0 | 0.26% | 0.00% |
| April 6, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 2620 | $2.00 | 1,003,971.0000 | 0 | 0.26% | 0.00% |
| April 5, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 4687 | $2.18 | 187,100.0000 | 0 | 2.44% | 0.00% |
| April 5, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 25220 | $2.18 | 1,006,591.0000 | 0 | 2.44% | 0.00% |
| April 5, 2023 | Damora Therapeutics, Inc. | $DMRA | ORBIMED ADVISORS LLC | TenPercentOwner | S | Common Stock | 63058 | $2.18 | 2,516,599.0000 | 0 | 2.44% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | ORBIMED ADVISORS LLC | Director | A | Common Stock | 288114 | $0.00 | 288,114.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | ORBIMED ADVISORS LLC | Director | A | Common Stock | 7611458 | $0.00 | 8,661,225.0000 | 0 | 725.06% | 0.00% |
| Feb. 15, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | P | Common Stock | 14329 | $23.00 | 299,205.0000 | 0 | 5.03% | 0.00% |
| Feb. 15, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | P | Common Stock | 37049 | $23.00 | 773,607.0000 | 0 | 5.03% | 0.00% |
| Feb. 15, 2023 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | P | Common Stock | 57318 | $23.00 | 1,196,825.0000 | 0 | 5.03% | 0.00% |
| Dec. 29, 2022 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | J | Common Stock | 1139507 | $0.00 | 1,139,507.0000 | 0 | 9999.99% | 0.00% |
| Dec. 29, 2022 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | J | Common Stock | 582622 | $0.00 | 582,622.0000 | 0 | 9999.99% | 0.00% |
| Dec. 29, 2022 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | J | Common Stock | 284876 | $0.00 | 284,876.0000 | 0 | 9999.99% | 0.00% |
| Dec. 29, 2022 | Disc Medicine, Inc. | $IRON | ORBIMED ADVISORS LLC | Director | J | Common Stock | 153936 | $0.00 | 736,558.0000 | 0 | 26.42% | 0.00% |